The device, which includes Ricrolin+ and a new Power Generator I-ON CXL, allows the riboflavin to penetrate in the cornea and treat keratoconus.
Oogroup executive vice president Fulvio Foschini said the CE mark approval has allowed SOOFT italia to serve its customers and patients with clear advantages for both the ophthalmogists and patients.
"Iontophoresis is an excellent delivery system, which allowed to perform the entire cross linking procedure in about 10-15 minutes, instead than 1 hour as for the actual procedures in the market," Foschini added.
"This new technology will add to our current patent portfolio, allowing SOOFT italia S.p.A. to reinforce its worldwide leadership in the field of Corneal Collagen Cross Linking."
